PHASE Scientific has secured $34 million in Series A funding round, marking a significant step forward in the company’s mission to transform women’s health diagnostics. The round was led by Value Partners Group, with additional participation from healthcare-focused investors.
The funding will support further development and commercialization of the company’s PHASIFY urine concentration technology, which enhances the detection of disease biomarkers in urine samples. According to PHASE Scientific, this technology captures nearly ten times more biomarkers than conventional methods, paving the way for non-invasive testing options, particularly in cervical cancer and HPV screening.
The company has already developed a urine-based HPV test designed to make cervical cancer screening more comfortable and accessible. In a clinical study conducted with Peking University Shenzhen Hospital, the test showed 93.4% sensitivity in identifying CIN2+ lesions and over 97% concordance with gold-standard physician-collected HPV tests for types 16 and 18.
“The successful close of this landmark Series A financing validates the transformative potential of our technology and the growing global demand for accessible, accurate early disease detection,” said Dr. Ricky Chiu, Founder, Chairman and CEO of PHASE Scientific.
“With this capital, we will accelerate R&D and commercialization efforts to bring a comprehensive suite of next-generation urine-based diagnostics to market.”
The PHASIFY platform enables patients to collect samples at home, eliminating the discomfort and inconvenience associated with traditional cervical screenings, which often require clinical visits. By lowering the barrier to routine testing, PHASE Scientific aims to improve early detection rates and reduce cases of cervical cancer.
Beyond HPV, the company is expanding its technology to support a broader range of women’s health diagnostics. To date, PHASE Scientific has launched more than 30 diagnostic products and distributed over 100 million tests across 30+ countries.
“We are delighted to become a partner of PHASE Scientific as it rapidly grows and addresses critical unmet needs in early disease detection,” said Dr. Chuen Yan Leung, Partner at Value Partners Group. “Its innovative technology represents a paradigm shift, offering an unparalleled combination of clinical precision and patient-centric solutions.”
Founded in 2015, PHASE Scientific operates in Hong Kong, Southern California, and China’s Greater Bay Area, with a focus on delivering next-generation diagnostics that empower early intervention and better health outcomes.
